

# Herbal Nano pharmacology: Integrating Traditional Medicine with Modern Pharmaceutical Technologies

Danish Banjare<sup>1</sup>, Menka Banchhor<sup>2</sup>, Dorendra Deshmukh<sup>3</sup>, Chhunni Pali<sup>4</sup>, Deleshwar Kumar<sup>1\*</sup>

<sup>1</sup>Kamla Institute of Pharmaceutical Sciences, Junwani, Bhilai, C.G. 490020.

<sup>2</sup>Rungta College of Pharmaceutical sciences and research, Kohka, Bhilai, C.G. 490023.

<sup>3</sup>Maitri College of Pharmacy, Anjora, Durg, 491001.

<sup>4</sup>Gracious College of Pharmacy, Kawardha, Kabirdham, C.G. 491995.

\*Corresponding Author E-mail: [deleshwarkumar54@gmail.com](mailto:deleshwarkumar54@gmail.com)

---

## Abstract:

Herbal medicine has a long-standing history in the treatment of various ailments, but conventional formulations often suffer from poor solubility, low bioavailability, and variable pharmacokinetics. Integration of nanotechnology with herbal pharmacology—termed herbal nanopharmacology—offers solutions to these limitations, enabling targeted delivery, controlled release, and enhanced therapeutic efficacy. This review explores recent advances in herbal nanocarriers, including liposomes, polymeric nanoparticles, solid lipid nanoparticles, and nanostructured lipid carriers, focusing on formulation strategies, characterization techniques, pharmacological applications, and clinical translation challenges. Future perspectives emphasize precision herbal therapy, synergistic formulations, and regulatory considerations.

**Keywords:** Herbal Medicine, Nanopharmacology, Nanoparticles, Targeted Delivery, Bioavailability, Controlled Release, Phytotherapy.

---

Received: Nov. 18, 2025

Revised: Dec.20, 2025

Accepted: Jan. 28, 2026

Published: Feb 8, 2026

DOI: <https://doi.org/10.64062/JPGMB.Vol2.Issue1.3>

<https://jpgmb.com/1/issue/archive>

*This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)*

---

## 1. Introduction

Herbal therapeutics have been an integral part of human healthcare for thousands of years, celebrated for their broad spectrum of pharmacological activities—including anti-inflammatory, anticancer, antioxidant, and neuroprotective effects. From Ayurvedic

concoctions to Traditional Chinese Medicine, plant-based remedies have played a pivotal role in maintaining health and treating diseases long before the advent of synthetic drugs <sup>1</sup>. However, despite their immense therapeutic potential, conventional herbal formulations face several critical limitations that hinder their clinical effectiveness. Many plant-derived bioactive compounds exhibit poor aqueous solubility and low systemic bioavailability, resulting in inadequate absorption and minimal therapeutic impact <sup>2</sup>. Moreover, these compounds are often chemically unstable and prone to degradation in the harsh environment of the gastrointestinal tract. Another significant challenge lies in their non-specific distribution, which often leads to reduced efficacy and increased variability in therapeutic outcomes.

This is where nanotechnology steps in as a game changer—bridging the gap between ancient wisdom and modern pharmaceutical innovation. By encapsulating or conjugating herbal actives into nanoscale carriers, it becomes possible to protect delicate phytochemicals from premature degradation, enhance their solubility, and achieve controlled and targeted drug delivery <sup>3</sup>. Nanocarriers such as liposomes, polymeric nanoparticles, solid lipid nanoparticles, and nanoemulsions can improve the pharmacokinetic and pharmacodynamic profiles of herbal drugs, ensuring they reach their intended site of action more effectively. This integration not only boosts therapeutic efficacy but also enhances patient compliance through lower dosing frequency and reduced side effects <sup>4</sup>.

The rapidly emerging field of herbal nanopharmacology is therefore revolutionizing the way traditional medicine is perceived and utilized in modern healthcare. It combines the biological richness of herbs with the precision of nanotechnology, paving the way for the development of next-generation natural therapeutics with improved stability, bioavailability, and clinical performance <sup>5</sup>. This convergence holds immense promise for creating safer, more effective, and patient-friendly treatment modalities for a wide range of diseases.

## **2. Classification of Herbal Nanocarrier Systems**

The evolution of nanotechnology has given a modern edge to traditional herbal medicine, leading to the development of advanced nanocarrier systems designed to improve the delivery, stability, and therapeutic efficacy of plant-based bioactives <sup>6</sup>. These carriers protect sensitive phytochemicals from degradation, enhance their solubility and bioavailability, and enable targeted drug delivery. Herbal nanocarriers can be broadly classified into four major types: lipid-based nanocarriers, polymeric nanoparticles, dendrimers and micelles, and green-synthesized nanoparticles—each offering distinct advantages in formulation and therapeutic performance. Lipid-based nanocarriers are among the most extensively studied systems because of their biocompatibility and efficient drug loading capabilities <sup>7</sup>. Liposomes, which consist of phospholipid bilayers, can encapsulate both hydrophilic and hydrophobic phytochemicals, providing excellent protection against enzymatic degradation and promoting controlled release. Similarly, solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) are known for their ability to improve oral bioavailability, ensure prolonged circulation time, and deliver drugs in a controlled manner <sup>8</sup>. Their lipid nature mimics biological membranes, enhancing absorption and minimizing adverse effects—making them ideal for poorly soluble herbal compounds. Polymeric nanoparticles offer another powerful approach, particularly when sustained or targeted delivery is desired <sup>9</sup>. Made from biodegradable

polymers such as PLGA and chitosan, these nanoparticles provide controlled release and maintain steady drug levels over an extended period. What makes them especially promising is their ability to undergo surface functionalization, which allows precise targeting to specific tissues such as the liver, brain, or tumor sites. This targeted delivery minimizes systemic toxicity and improves therapeutic outcomes, positioning polymeric nanoparticles as a crucial tool in modern herbal drug formulation <sup>10</sup>. Dendrimers and micelles represent more sophisticated nanostructures with excellent drug delivery potential. Dendrimers, characterized by their highly branched, tree-like structure, offer high drug loading capacity and multiple surface sites for functional modification. This allows easy attachment of targeting molecules, enhancing site-specific delivery <sup>11</sup>. Polymeric micelles, on the other hand, are formed through the self-assembly of amphiphilic block copolymers, enabling them to solubilize hydrophobic phytochemicals efficiently. Their high stability in circulation and controlled release properties make them particularly suitable for improving the bioavailability of poorly soluble herbal drugs <sup>12</sup>. In recent years, green-synthesized nanoparticles have gained significant attention as an eco-friendly and cost-effective alternative. This approach uses plant extracts as natural reducing and stabilizing agents for synthesizing metal or metal oxide nanoparticles. The resulting nanomaterials combine the therapeutic potential of phytochemicals with the inherent antimicrobial, antioxidant, or anticancer properties of nanoparticles such as silver, gold, or zinc oxide <sup>13-14</sup>. This not only reduces the environmental footprint of nanoparticle production but also offers synergistic therapeutic benefits, making green-synthesized nanoparticles a promising frontier in herbal nanopharmacology. Overall, these herbal nanocarrier systems represent a powerful fusion of traditional medicine with cutting-edge nanotechnology. By enhancing stability, improving bioavailability, and enabling targeted delivery, they pave the way for more effective and clinically viable natural therapeutics <sup>15</sup>. (Table 1. )

**Table 1. Comparison of Herbal Nanocarrier Systems**

Nanocarrier	Composition	Size (nm)	Advantages	Challenges	Reference
Liposomes	Phospholipids	50–200	Biocompatible, protects bioactives	Stability, leakage	16
Polymeric NP	PLGA, chitosan	50–300	Controlled release, targeted delivery	Complex synthesis	17

SLN/NLC	Lipids + surfactants	50–250	Oral bioavailability enhancement	Limited drug loading	18
Dendrimers	Branched polymers	5–20	Multi-functional, high loading	Cost, toxicity potential	19
Micelles	Amphiphilic polymers	10–100	Solubilize hydrophobic drugs	Stability in vivo	20
Green-synthesized NP	Metal + plant extracts	10–100	Eco-friendly, synergistic effect	Reproducibility, characterization	21

### 3. Materials and Methods in Herbal Nanopharmacology


The development of effective herbal nanocarrier systems relies on carefully selected phytochemicals, biocompatible carrier materials, and precise fabrication techniques. Together, these components form the backbone of herbal nanopharmacology, ensuring that traditional bioactive compounds can be delivered with modern precision and stability. The choice of materials and methods depends on the chemical nature of the phytoconstituents, the intended route of administration, and the desired therapeutic effect <sup>22</sup>.

At the core of herbal nanopharmacology are active phytochemicals, which serve as the therapeutic agents. Commonly studied compounds include curcumin, quercetin, resveratrol, ginsenosides, and berberine, among others. These molecules are renowned for their potent pharmacological properties, such as anti-inflammatory, antioxidant, anticancer, and neuroprotective effects. However, their clinical translation is often hindered by poor solubility, instability, and low bioavailability <sup>23</sup>. Incorporating these bioactives into nanocarriers significantly enhances their therapeutic potential by improving absorption, protecting them from degradation, and enabling targeted delivery to specific tissues.

Equally important is the selection of polymers and lipids that act as carriers. Commonly used polymers include PLGA (poly lactic-co-glycolic acid) and chitosan, both of which are biodegradable, biocompatible, and suitable for controlled drug release <sup>24</sup>. Lipid-based materials such as phosphatidylcholine and triglycerides are also widely employed due to their natural compatibility with biological membranes, making them ideal for encapsulating lipophilic phytochemicals. These materials not only stabilize the active compounds but also influence the size, surface charge, and release profile of the resulting nanoparticles <sup>25</sup>.

The fabrication techniques used to produce herbal nanocarriers play a crucial role in determining their structure, stability, and functionality. Among the most common methods is solvent evaporation, which allows for the encapsulation of both hydrophobic and hydrophilic compounds with high efficiency <sup>26</sup>. Nanoprecipitation offers a simpler and faster approach, particularly suitable for hydrophobic phytochemicals, resulting in uniform nanoparticle sizes. High-pressure homogenization is another widely used method, ideal for producing solid lipid nanoparticles and nanoemulsions with excellent stability and reproducibility <sup>27</sup>. (Table 2) Additionally, green synthesis methods are gaining momentum, utilizing plant extracts as natural reducing and stabilizing agents to fabricate metal or metal oxide nanoparticles without the use of toxic chemicals. Together, these materials and methods provide a versatile toolkit for designing and optimizing herbal nanocarrier systems that combine the time-tested potency of natural compounds with the technological sophistication of modern nanoscience <sup>28</sup>. By fine-tuning each component of the formulation process, researchers can achieve improved drug stability, enhanced therapeutic efficacy, and better patient compliance, paving the way for the next generation of plant-based nanomedicines <sup>29</sup>. (Figure 1)

**Figure 1.** Schematic of Herbal Nanocarrier Fabrication



**Table 2.** Characterization Techniques in Herbal Nanopharmacology

Parameter	Technique	Purpose	Reference
Size	DLS	Determine particle size and PDI	30
Morphology	TEM/SEM	Shape and surface visualization	31
Surface charge	Zeta potential	Stability and interaction prediction	32
Encapsulation	HPLC/UV-Vis	Quantify phytochemical loading	33
Stability	DSC, FTIR	Thermal and chemical integrity	34

#### 4. Physicochemical Characterization

A critical step in the development of herbal nanocarriers is their physicochemical characterization, which ensures the stability, functionality, and therapeutic reliability of the formulation. Proper characterization not only confirms the successful fabrication of nanoparticles but also provides insights into how these systems will behave in biological environments. Parameters such as particle size, surface charge, morphology, encapsulation efficiency, and stability are meticulously analyzed using advanced analytical techniques<sup>35</sup>. One of the most essential parameters is particle size and its distribution, which directly influences drug release, cellular uptake, biodistribution, and overall therapeutic efficacy. Typically, Dynamic Light Scattering (DLS) is employed to determine the average particle size and polydispersity index (PDI) of herbal nanocarriers. A narrow size distribution indicates uniformity in formulation, which is crucial for consistent drug delivery performance<sup>36</sup>. Another important factor is the surface charge, which affects the stability and interaction of nanoparticles with biological membranes. This is measured using zeta potential analysis. A high absolute zeta potential value (either positive or negative) typically suggests good colloidal stability, reducing the likelihood of particle aggregation during storage or upon administration<sup>37</sup>. The morphology of nanoparticles provides visual confirmation of their shape, size, and surface structure. Techniques like Transmission Electron Microscopy (TEM) and Scanning Electron Microscopy (SEM) offer high-resolution images, revealing whether the particles are spherical, rod-shaped, or irregular<sup>38</sup>. This structural insight is particularly important because the shape and surface texture of nanoparticles can influence their biological interactions and cellular uptake. In addition, determining encapsulation efficiency and drug loading is vital to evaluating how much of the active phytochemical has been successfully incorporated into the nanocarrier system<sup>39</sup>. Techniques such as UV-Visible spectrophotometry (UV-Vis) and High-Performance Liquid Chromatography (HPLC) are commonly used for this purpose. High encapsulation efficiency ensures maximum therapeutic benefit, while appropriate drug loading helps achieve the desired dosage with minimal excipient use<sup>40</sup>. Lastly, assessing the thermal and chemical stability of the formulation ensures that the nanoparticles can maintain their integrity during storage and under physiological conditions. Differential Scanning Calorimetry (DSC) provides information about the thermal behavior and phase transitions of the formulation, while Fourier Transform Infrared Spectroscopy (FTIR) helps identify any potential chemical interactions between the active compound and the carrier materials<sup>41</sup>. Together, these techniques help confirm that the phytochemicals remain stable and active within the nanocarrier. In summary, physicochemical characterization plays a pivotal role in ensuring the quality, safety, and efficacy of herbal nanocarrier systems. By thoroughly analyzing these key parameters, researchers can optimize their formulations for enhanced therapeutic performance, paving the way for successful clinical translation of herbal nanomedicines<sup>42</sup>.

#### 5. Mechanisms of Drug Loading and Release


The mechanisms of drug loading and release are central to the therapeutic effectiveness of herbal nanocarrier systems. These mechanisms determine how the bioactive phytochemicals are incorporated into the carrier and how they are subsequently delivered at the target site in a controlled and predictable manner<sup>43</sup>. By understanding and manipulating these processes,

researchers can optimize formulations for maximum efficacy, minimal side effects, and prolonged therapeutic action. In general, the release of drugs from herbal nanocarriers follows three main mechanisms: diffusion-controlled, degradation-controlled, and stimuli-responsive release <sup>44</sup>.

In the diffusion-controlled mechanism, the bioactive compound is dispersed within the nanocarrier matrix, and its release occurs gradually as it diffuses through the polymeric or lipid structure. This slow and sustained release ensures a consistent therapeutic concentration in the bloodstream over an extended period <sup>45</sup>. Such a mechanism is particularly advantageous for phytochemicals with short half-lives, as it helps maintain their activity without the need for frequent dosing. The release rate can be fine-tuned by altering the carrier composition, particle size, and surface characteristics, making this one of the most commonly employed strategies in herbal nanopharmacology <sup>46</sup>.

The degradation-controlled mechanism involves the release of the active compound as the carrier material itself undergoes degradation. This typically occurs with biodegradable polymers like PLGA or chitosan, where the gradual breakdown of the matrix allows the encapsulated phytochemicals to be released in a time-dependent manner. This approach is especially useful for long-term therapies, as it provides a controlled, zero-order release profile, ensuring that the drug remains active over prolonged durations without rapid initial bursts <sup>47</sup>. The degradation rate can be engineered by modifying the polymer type, molecular weight, and fabrication technique. A more advanced strategy is the stimulus-responsive mechanism, in which drug release is triggered by specific environmental factors such as pH, temperature, enzymatic activity, or redox conditions. This smart delivery system allows the nanocarriers to remain stable in circulation but release their cargo precisely at the target site, such as a tumor microenvironment or inflamed tissue, where the conditions differ from normal physiological states <sup>48</sup>. For example, acidic pH in tumor tissues can trigger the breakdown of pH-sensitive carriers, ensuring that the herbal drug is released exactly where it is needed. This approach enhances therapeutic specificity, minimizes systemic side effects, and maximizes drug efficacy <sup>49</sup>.

Overall, understanding these drug loading and release mechanisms allows for the rational design of herbal nanocarrier systems tailored to specific therapeutic goals. Whether through sustained diffusion, controlled degradation, or intelligent stimuli-responsiveness, these mechanisms transform traditional phytochemicals into modern, precise, and efficient therapeutic agents, opening new horizons in targeted natural medicine <sup>50</sup>. (Figure 2)

**Figure 2.** Drug Release Mechanisms from Herbal Nanocarriers

## 6. Pharmacological Applications

Herbal nanopharmacology is opening up new frontiers in therapeutic intervention by enhancing the pharmacological potential of natural compounds through advanced delivery strategies. Nanocarriers not only improve the solubility, stability, and bioavailability of phytochemicals but also enable precise targeting of diseased tissues, leading to better therapeutic outcomes with fewer side effects. Over the past decade, these nanocarrier systems have been extensively explored in several major therapeutic areas, including cancer treatment, neuroprotection, inflammation control, and antimicrobial therapy<sup>51</sup>. One of the most impactful applications of herbal nanocarriers is in oncology, where targeted delivery and enhanced cytotoxic activity are critical. Curcumin-loaded polymeric nanoparticles have shown a remarkable ability to accumulate in tumor tissues via the enhanced permeability and retention (EPR) effect, resulting in increased local concentration of the drug and improved anticancer efficacy<sup>52</sup>. By protecting curcumin from premature degradation and ensuring sustained release, these nanoparticles can significantly reduce tumor growth and enhance apoptosis in cancer cells. In addition, green-synthesized silver nanoparticles prepared using herbal extracts have demonstrated synergistic anticancer activity, combining the inherent cytotoxicity of silver ions with the therapeutic effects of phytochemicals. This dual-action approach has shown promise against various cancer cell lines while minimizing harm to normal cells<sup>53</sup>. The brain has always posed a significant challenge for drug delivery due to the blood–brain barrier (BBB), but herbal nanocarriers are changing the game. Phytochemicals such as resveratrol and ginsenosides, when encapsulated in nanoparticle systems, have been shown to efficiently cross the BBB, delivering neuroprotective agents directly to the central nervous system. This targeted approach improves cognitive function, reduces oxidative stress, and protects neurons from degenerative damage associated with conditions like Alzheimer’s and Parkinson’s disease<sup>54</sup>. By enhancing brain bioavailability and ensuring controlled release, these nanocarriers help overcome one of the biggest hurdles in neuropharmacology. Inflammation lies at the root of numerous chronic diseases, and herbal nanocarriers offer an effective and safer alternative to conventional anti-

inflammatory drugs. Quercetin and berberine nanoparticles are prime examples, as they exhibit enhanced bioavailability and targeted distribution, leading to more potent anti-inflammatory activity with lower doses <sup>55</sup>. These formulations help reduce systemic inflammation by modulating cytokine levels, inhibiting pro-inflammatory pathways, and promoting immune balance. The use of nanocarriers not only improves therapeutic outcomes but also reduces gastrointestinal side effects often associated with high-dose oral administration of free compounds. Another major area where herbal nanopharmacology is making a strong impact is in antimicrobial therapy <sup>56</sup>. Metal nanoparticles synthesized using plant extracts have shown potent broad-spectrum activity against bacteria, viruses, and fungi. The combination of phytochemicals and metals like silver, gold, or zinc oxide enhances the antimicrobial potential through multiple mechanisms—such as disrupting microbial membranes, generating reactive oxygen species, and interfering with cellular pathways <sup>57</sup>. These nanostructures hold promise as alternatives to conventional antibiotics, particularly in the fight against multidrug-resistant pathogens. In essence, the pharmacological applications of herbal nanocarriers span multiple therapeutic domains, offering enhanced efficacy, better targeting, and improved patient compliance <sup>58</sup>. By merging the wisdom of traditional medicine with the precision of nanotechnology, researchers are laying the foundation for a new generation of natural, smart, and efficient therapeutic solutions <sup>59</sup>. (Table 3)

**Table 3.** Representative Herbal Nanopharmacological Formulations and Applications

Phytochemical	Nanocarrier	Target Disease	Observed Benefit	Reference
Curcumin	PLGA NP	Cancer	Enhanced tumor targeting, bioavailability	60
Resveratrol	Liposome	Neurodegeneration	BBB penetration, reduced oxidative stress	61
Berberine	SLN	Diabetes	Controlled release, improved absorption	62
Quercetin	Micelle	Inflammation	Increased systemic stability	63
Green AgNP	Herbal extract	Bacterial infection	Broad-spectrum antimicrobial	64

## 7. Clinical Translation and Regulatory Challenges

Despite the significant advances in herbal nanopharmacology, translating these promising formulations from the laboratory to clinical use presents several challenges. One of the primary concerns is the stability and reproducibility of herbal nanocarriers <sup>65</sup>. Achieving batch-to-batch consistency is often difficult due to the complex nature of plant-derived compounds and the variability inherent in natural sources. Minor changes in raw material quality, processing conditions, or fabrication techniques can lead to variations in particle size, encapsulation efficiency, and overall therapeutic performance, which may affect safety and efficacy <sup>66</sup>.

Toxicity is another critical factor that must be carefully evaluated. The composition, size, and surface chemistry of nanoparticles can significantly influence their interactions with biological systems<sup>67</sup>. While many polymers and lipids are biocompatible, certain metal-based or chemically modified nanoparticles may induce cytotoxicity, oxidative stress, or immune reactions. Thorough preclinical safety studies are therefore essential to ensure that the herbal nanocarriers do not cause unintended adverse effects when administered to patients<sup>68</sup>.

Regulatory pathways for herbal nanopharmaceuticals also pose a significant hurdle. Unlike conventional drugs or single-compound formulations, herbal nanomedicines are complex, multicomponent systems, and standardized guidelines for their evaluation are largely lacking. Regulatory agencies often face challenges in defining quality control parameters, determining appropriate clinical endpoints, and assessing long-term safety<sup>69</sup>. This lack of clear guidance can slow down the approval process and limit the clinical adoption of promising herbal nanotherapeutics. Scale-up of production is another practical concern<sup>70</sup>. While laboratory-scale formulations can be carefully controlled, maintaining quality, encapsulation efficiency, and uniform particle characteristics during industrial-scale manufacturing is challenging. Differences in mixing, temperature control, and processing times can result in inconsistent products, which may compromise clinical efficacy<sup>71</sup>. Addressing these scale-up issues requires robust process optimization, advanced manufacturing technologies, and stringent quality assurance protocols.

Overall, while herbal nanopharmacology offers exciting therapeutic potential, overcoming these clinical translation and regulatory challenges is crucial for moving these formulations from bench to bedside<sup>72</sup>. Success in this area will depend on careful standardization, rigorous safety assessment, and the development of regulatory frameworks tailored to the unique complexities of herbal nanomedicines.

## **8. Future Perspectives**

The field of herbal nanopharmacology is poised for transformative growth, driven by advances in technology, materials science, and personalized medicine. One promising direction is the development of precision herbal nanomedicine, which integrates genomic information with phytopharmacology to design patient-specific therapies<sup>73</sup>. By understanding an individual's genetic makeup and disease profile, it becomes possible to tailor herbal nanocarrier formulations for optimal efficacy and minimal side effects, ushering in a new era of personalized natural therapeutics<sup>74</sup>.

Another emerging trend is the use of multi-functional carriers that can deliver multiple bioactive compounds simultaneously. This approach leverages the synergistic effects of different phytochemicals, enhancing therapeutic outcomes while reducing the need for multiple medications<sup>75</sup>. Such carriers are particularly valuable in managing complex diseases such as cancer, neurodegenerative disorders, and chronic inflammatory conditions, where a single bioactive may not be sufficient to produce the desired effect<sup>76</sup>.

Stimuli-responsive systems are also gaining attention, allowing targeted drug release in response to specific environmental triggers such as pH, temperature, enzymatic activity, or

redox conditions. This strategy ensures that herbal drugs are released precisely at the site of disease, such as tumor tissues or inflamed regions, thereby maximizing therapeutic efficacy and minimizing systemic side effects <sup>77</sup>. The design of such intelligent systems is becoming increasingly sophisticated with advances in material science and nanotechnology.

Integration with artificial intelligence and big data analytics represents another exciting frontier. AI can predict the optimal combination of phytochemicals, select suitable nanocarrier platforms, and model drug release kinetics to achieve desired therapeutic outcomes <sup>78</sup>. By analyzing large datasets from preclinical and clinical studies, machine learning algorithms can accelerate the discovery and optimization of herbal nanomedicines, making the development process faster, more cost-effective, and more precise <sup>79</sup>. Finally, sustainable and green approaches are likely to shape the future of herbal nanopharmacology. Eco-friendly synthesis methods, including green chemistry and plant-mediated nanoparticle fabrication, reduce environmental impact while maintaining therapeutic efficacy. Scalable production techniques that adhere to sustainability principles will be essential for translating laboratory innovations into commercially viable and environmentally responsible products <sup>80</sup>

## 9. Conclusion

Herbal nanopharmacology represents a significant advancement in the integration of traditional medicine with modern pharmaceutical technology. By addressing the long-standing challenges of poor solubility, chemical instability, and low bioavailability, nanocarrier systems have transformed the therapeutic potential of herbal compounds. These nanoscale delivery platforms facilitate targeted drug delivery, controlled and sustained release, and enhanced pharmacological efficacy, thereby improving patient outcomes and paving the way for more reliable clinical applications. The continued evolution of this field is expected to be driven by innovations in personalized therapy, where patient-specific genetic and disease profiles guide the selection and formulation of herbal nanomedicines. Stimuli-responsive systems that release phytochemicals precisely at diseased sites will further improve treatment specificity and minimize side effects. Moreover, the integration of artificial intelligence and big data analytics can optimize the design of nanocarriers, predict synergistic phytochemical combinations, and accelerate the translation of laboratory research into clinically viable therapeutics. In essence, herbal nanopharmacology bridges ancient wisdom with modern pharmaceuticals, offering a pathway to more effective, targeted, and patient-friendly natural therapies. With ongoing research, technological innovation, and regulatory advancement, this interdisciplinary field holds immense promise for shaping the future of medicine, combining the best of traditional herbal knowledge with the precision and sophistication of contemporary drug delivery systems.

## References

1. Alghamdi, M. (2018). Herbal medicine use by Saudi patients with chronic diseases: A cross-sectional study (experience from Southern Region of Saudi Arabia). *Journal of Health Specialties*, 6(2), 77. [http://scholar.google.com/scholar\\_lookup?title=Herbal%20medicine%20use%20by%20Saudi%20patients%20with%20chronic%20diseases%3A%20a%20crosssectional%20study%20%28experience%20from%20Southern%20Region%20of%20Saudi%20A](http://scholar.google.com/scholar_lookup?title=Herbal%20medicine%20use%20by%20Saudi%20patients%20with%20chronic%20diseases%3A%20a%20crosssectional%20study%20%28experience%20from%20Southern%20Region%20of%20Saudi%20A)

- [rabia%29&author=M.%20Alghamdi&journal=J%20Health%20Special&volume=6&issue=2&pages=77&publication\\_year=2018](#)
- Halberstein, R. A. (2005). Medicinal plants: Historical and cross-cultural usage patterns. *Annals of Epidemiology*, 15(9), 686–699. [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list\\_uids=15921929](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15921929)
  - Mukherjee, P. K. (2001). Evaluation of Indian traditional medicine. *Drug Information Journal*, 35(2), 623–632. [http://scholar.google.com/scholar\\_lookup?title=Evaluation%20of%20Indian%20traditional%20medicine&author=PK.%20Mukherjee&journal=Drug%20Inf%20J&volume=35&issue=2&pages=623-632&publication\\_year=2001](http://scholar.google.com/scholar_lookup?title=Evaluation%20of%20Indian%20traditional%20medicine&author=PK.%20Mukherjee&journal=Drug%20Inf%20J&volume=35&issue=2&pages=623-632&publication_year=2001)
  - Saad, B. (2006). Safety of traditional Arab herbal medicine. *Evidence-Based Complementary and Alternative Medicine*, 3(4), 433–439. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1697757>
  - Seema, A. (2014). Recent development of herbal formulation—a novel drug delivery system. *International Ayurvedic Medical Journal*, 2(6), 952–958. [http://scholar.google.com/scholar\\_lookup?title=Recent%20development%20of%20herbal%20formulation%20of%20a%20novel%20drug%20delivery%20system&author=A.%20Seema&journal=Int%20Ayurved%20Med%20J&volume=2&issue=6&pages=952-958&publication\\_year=2014](http://scholar.google.com/scholar_lookup?title=Recent%20development%20of%20herbal%20formulation%20of%20a%20novel%20drug%20delivery%20system&author=A.%20Seema&journal=Int%20Ayurved%20Med%20J&volume=2&issue=6&pages=952-958&publication_year=2014)
  - Chatfield, K., Salehi, B., Sharifi-Rad, J., & Afshar, L. (2018). Applying an ethical framework to herbal medicine. *Evidence-Based Complementary and Alternative Medicine*. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169226/>
  - Bonifácio, B. V., da Silva, P. B., Ramos, M. A. D. S., Negri, K. M. S., Bauab, T. M., & Chorilli, M. (2014). Nanotechnology-based drug delivery systems and herbal medicines: A review. *International Journal of Nanomedicine*, 9, 1–15. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC24363556>
  - Zhang, X. (2004). Traditional medicine: Its importance and protection. *Protecting and Promoting Traditional Knowledge: Systems. National Experimental International Dimensions, Part 1*, 3–6.
  - Mishra, S. (2019). Bioinspired nanocomposites: Applications in disease diagnosis and treatment. *Pharmaceutical Nanotechnology*, 7(3), 206–219. [http://scholar.google.com/scholar\\_lookup?title=Bioinspired%20nanocomposites%20applications%20in%20disease%20diagnosis%20and%20treatment&author=S.%20Mishra&journal=Pharm%20Nanotechnol&volume=7&issue=3&pages=206-219&publication\\_year=2019](http://scholar.google.com/scholar_lookup?title=Bioinspired%20nanocomposites%20applications%20in%20disease%20diagnosis%20and%20treatment&author=S.%20Mishra&journal=Pharm%20Nanotechnol&volume=7&issue=3&pages=206-219&publication_year=2019)
  - Nigar, S. (2016). Molecular insights into the role of inflammation and oxidative stress in epilepsy. *Journal of Advanced Medical and Pharmaceutical Sciences*, 10(1), 1–9.
  - Pottoo, F. H. (2019). The synergistic effect of raloxifene, fluoxetine, and bromocriptine protects against Pilocarpine-induced status Epilepticus and temporal lobe epilepsy. *Molecular Neurobiology*, 56(2), 1233–1247.
  - Ahmad, N. (2019). Tamarindus indica fruit: Pharmacognostical standardization, detection of contaminants, and in vitro antioxidant activity. *Journal of Pharmacy and Bioallied Sciences*, 11(4), 355.

13. Javed, M. N. (2019). QbD applications for the development of nanopharmaceutical products. *Pharmaceutical Quality & Design*, 24, 229–253.
14. Patra, P. (2018). Phytochemical investigation and hepatoprotective effect of *Scoparia dulcis* against carbon tetrachloride-induced liver damage in rats. *International Journal of Pharmaceutical Sciences & Research*, 9(7), 1086–1092.
15. Pottoo, F. H. (2019). Estrogen and serotonin: Complexity of interactions and implications for epileptic seizures and Epileptogenesis. *Current Neuropharmacology*, 17(3), 214–231.
16. Barkat, M. A. (2017). Nanosuspension-based Aloe vera gel of silver sulfadiazine with improved wound healing activity. *AAPS PharmSciTech*, 18(8), 3274–3285.
17. Barkat, M. A. (2018). Therapeutic intervention of gel containing nano-sized and micron-sized silver sulfadiazine gel on second-degree burn: A comparative study. *International Journal of Lower Extremity Wounds*, 17(3), 176–183.
18. Jachak, S. M., & Saklani, A. (2007). Challenges and opportunities in drug discovery from plants. *Current Science*, 92(9), 1251–1257.
19. Parasuraman, S. (2018). Herbal drug discovery: Challenges and perspectives. *Current Pharmacogenomics and Personalized Medicine*. <http://www.eurekaselect.com/161425/article>
20. Palav, Y. K., & D'mello, P. M. (2006). Standardization of selected Indian medicinal herbal raw materials containing polyphenols as major phytoconstituents. *Indian Journal of Pharmaceutical Sciences*, 68(4). <https://www.ijpsonline.com/abstract/standardization-of-selected-indian-medicinal-herbal-raw-materials-containing-polyphenols-as-major-phytoconstituents-3201.html>
21. Pottoo, F. H., Tabassum, N., Javed, M. N., Nigar, S., Sharma, S., Barkat, M. A., ... Ashraf, G. M. (2020). Raloxifene potentiates the effect of fluoxetine against maximal electroshock-induced seizures in mice. *European Journal of Pharmaceutical Sciences*, 146, 105261.
22. Mohammadian, M., Salami, M., Momen, S., Alavi, F., Eman-Djomeh, Z., & Moosavi-Movahedi, A. A. (2019). Enhancing the aqueous solubility of curcumin at acidic conditions through the complexation with whey protein nanofibrils. *Food Hydrocolloids*, 87, 902–914.
23. Basiliere, S., & Kerrigan, S. (2020). Temperature and pH-dependent stability of mitragyna alkaloids. *Journal of Analytical Toxicology*. <https://academic.oup.com/jat/advancearticle/doi/10.1093/jat/bkz103/5693674>
24. Ghaffar, A., Yameen, B., Latif, M., & Malik, M. I. (2020). pH-sensitive drug delivery systems. In M. R. Shah, M. Imran, & S. Ullah (Eds.), *Metal nanoparticles for drug delivery and diagnostic applications* (pp. 259–278). Elsevier. <http://www.sciencedirect.com/science/article/pii/B9780128169605000148>
25. Louisse, J., Rijkers, D., Stoop, G., Holleboom, W. J., Delagrang, M., Molthof, E., ... Peijnenburg, A. A. C. M. (2019). Determination of genotoxic potencies of pyrrolizidine alkaloids in HepaRG cells using the  $\gamma$ H2AX assay. *Food and Chemical Toxicology*, 131, 110532.
26. Dhiman, A., Nanda, A., & Ahmad, S. (2012). Novel herbal drug delivery system (NHDDS): The need of the hour. *IPCBE*, 49, 171–175.

27. Javed, M. N., Kohli, K., & Amin, S. (2018). Risk assessment integrated QbD approach for development of optimized bicontinuous mucoadhesive lim
28. icubes for oral delivery of Rosuvastatin. *AAPS PharmSciTech*, 19(3), 1377–1391.
29. Choudhary, A. (2011). An overview of advances in the standardization of herbal drugs. *Journal of Pharmacy Education and Research*, 2(2), 55.
30. Devi, V. K., Jain, N., & Valli, K. S. (2010). Importance of novel drug delivery systems in herbal medicines. *Pharmacognosy Reviews*, 4(7), 27–31.
31. Haneef, J., Shaharyar, M., Husain, A., Rashid, M., Mishra, R., Siddique, N. A., & Pal, M. (2013). Analytical methods for the detection of undeclared synthetic drugs in traditional herbal medicines as adulterants. *Drug Testing and Analysis*, 5(8), 607–613.
32. Khan, F. A., Almohazey, D., Alomari, M., & Almofty, S. A. (2018). Impact of nanoparticles on neuron biology: Current research trends. *International Journal of Nanomedicine*, 13, 2767–2776.
33. Pottoo, F. H., Barkat, M. A., Harshita, A. M. A., Javed, M. N., Jamal, Q. M. S., & Kamal, M. A. (2019). Nanotechnology-based miRNA intervention in the therapeutic management of neuroblastoma. *Seminars in Cancer Biology*. <http://www.sciencedirect.com/science/article/pii/S1044579X1930224X>
34. Yousuf, S., Salim, S., Ahmad, M., Ahmed, A. S., Ansari, M. A., & Islam, F. (2005). Protective effect of Khamira Abresham Uood Mastagiwala against free radical-induced damage in focal cerebral ischemia. *Journal of Ethnopharmacology*, 99(2), 179–184.
35. Ansari, S. H., Islam, F., & Sameem, M. (2012). Influence of nanotechnology on herbal drugs: A review. *Journal of Advanced Pharmaceutical Technology & Research*, 3(3), 142–146.
36. Chakraborty, K., Shivakumar, A., & Ramachandran, S. (2016). Nano-technology in herbal medicines: A review. *International Journal of Herbal Medicine*, 4, 21–27.
37. Leonarduzzi, G., Testa, G., Sottero, B., Gamba, P., & Poli, G. (2010). Design and development of nanovehicle-based delivery systems for preventive or therapeutic supplementation with flavonoids. *Current Medicinal Chemistry*, 17(1), 74–95.
38. Verma, H., Prasad, S. B., & Yashwant, S. H. (2013). Herbal drug delivery system: A modern era perspective. *International Journal of Current Pharmaceutical Review and Research*, 4, 88–101.
39. Watkins, R. (2015). Natural product-based nanomedicine: Recent advances and issues. *International Journal of Nanomedicine*, 10, 6055–6074.
40. Sharma, S., Noushad Javed, M., Pottoo, F., Rabbani, S. A., Barkat, M. A., Harshita, ... Amir, M. (2019). Bioresponse-inspired nanomaterials for targeted drug and gene delivery. *Pharmaceutical Nanotechnology*, 7(3), 220–233.
41. Alam, M. S., Javed, M. N., Pottoo, F. H., Waziri, A., Almalki, F. A., Hasnain, M. S., ... Saifullah, M. K. (2019). QbD approached the comparison of the reaction mechanism in microwave-synthesized gold nanoparticles and their superior catalytic role against hazardous nitro-dye. *Applied Organometallic Chemistry*, 33(9), e5071.
42. Wang, R., Zhao, Z., Han, Y., Hu, S., Opoku-Damoah, Y., Zhou, J., ... Ding, Y. (2017). Natural particulates inspired specific-targeted codelivery of siRNA and paclitaxel for collaborative antitumor therapy. *Molecular Pharmaceutics*, 14(9), 2999–3012.
43. Tahara, Y., Yoshikawa, T., Sato, H., Mori, Y., Zahangir, M. H., Kishimura, A., ... Katayama, Y. (2017). Encapsulation of a nitric oxide donor into a liposome to boost

- the enhanced permeation and retention (EPR) effect. *Medicinal Chemistry Communications*, 8(2), 415–421.
44. Sintov, A. C., & Botner, S. (2006). Transdermal drug delivery using microemulsion and aqueous systems: Influence of skin storage conditions on the in vitro permeability of diclofenac from aqueous vehicle systems. *International Journal of Pharmaceutics*, 311(1–2), 55–62.
  45. Gainetdinov, R. R., Mohn, A. R., & Caron, M. G. (2001). Genetic animal models: Focus on schizophrenia. *Trends in Neurosciences*, 24(10), 527–533. [https://doi.org/10.1016/S0166-2236\(00\)01973-6](https://doi.org/10.1016/S0166-2236(00)01973-6)
  46. Winship, I. R., Dursun, S. M., Baker, G. B., Balista, P. A., Kandratavicius, L., Maia-de-Oliveira, J. P., ... Lanaro, C. (2019). An overview of animal models related to schizophrenia. *Canadian Journal of Psychiatry*, 64(1), 5–17. <https://doi.org/10.1177/0706743718799406>
  47. Lee, J., Lin, E.-W., Lau, U. Y., Hedrick, J. L., Bat, E., & Maynard, H. D. (2013). Trehalose glycopolymers as excipients for protein stabilization. *Biomacromolecules*, 14(7), 2561–2569. <https://doi.org/10.1021/bm4004184>
  48. Mancini, R. J., Lee, J., & Maynard, H. D. (2013). Trehalose glycopolymers for stabilization of proteins. *Biomacromolecules*, 14(7), 2570–2577. <https://doi.org/10.1021/bm4004193>
  49. Pottoo, F. H., Tabassum, N., Javed, M. N., Nigar, S., Sharma, S., Barkat, M. A., & Ashraf, G. M. (2020). Raloxifene potentiates the effect of fluoxetine against maximal electroshock-induced seizures in mice. *European Journal of Pharmaceutical Sciences*, 146, 105261. <https://doi.org/10.1016/j.ejps.2020.105261>
  50. Mohammadian, M., Salami, M., Momen, S., Alavi, F., Emam-Djomeh, Z., & Moosavi-Movahedi, A. A. (2019). Enhancing the aqueous solubility of curcumin at acidic conditions through the complexation with whey protein nanofibrils. *Food Hydrocolloids*, 87, 902–914. <https://doi.org/10.1016/j.foodhyd.2018.08.032>
  51. Basiliere, S., & Kerrigan, S. (2020). Temperature and pH-dependent stability of mitragyna alkaloids. *Journal of Analytical Toxicology*. Advance online publication. <https://doi.org/10.1093/jat/bkz103>
  52. Shivanand, P. (2010). Phytosomes: Technical revolution in phytomedicine. *International Journal of PharmTech Research*, 2(1), 627–631.
  53. Das, J. (2012). Poly(lactide-co-glycolide) encapsulated extract of *Phytolacca decandra* demonstrates better intervention against induced lung adenocarcinoma in mice and on A549 cells. *European Journal of Pharmaceutical Sciences*, 47(2), 313–324. <https://doi.org/10.1016/j.ejps.2012.05.011>
  54. Rajendran, R., Radhai, R., Kotresh, T. M., & Csiszar, E. (2013). Development of antimicrobial cotton fabrics using herb-loaded nanoparticles. *Carbohydrate Polymers*, 91(2), 613–617. <https://doi.org/10.1016/j.carbpol.2012.08.073>
  55. Mukerjee, A., & Vishwanatha, J. K. (2009). Formulation, characterization, and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. *Anticancer Research*, 29(10), 3867–3875.
  56. Khoshnevisan, K., Maleki, H., Samadian, H., Shahsavari, S., Sarrafzadeh, M. H., Larijani, B., Dorkoosh, F. A., Haghpanah, V., & Khorramizadeh, M. R. (2018). Cellulose acetate electrospun nanofibers for drug delivery systems: Applications and

- recent advances. *Carbohydrate Polymers*, 198, 131–141. <https://doi.org/10.1016/j.carbpol.2018.06.071>
57. Semalty, A. (2010). Supramolecular phospholipids–polyphenolics interactions: The PHYTOSOME® strategy to improve the bioavailability of phytochemicals. *Fitoterapia*, 81(5), 306–314. <https://doi.org/10.1016/j.fitote.2009.12.008>
58. Andrade, C. A. S., Correia, M. T. S., Coelho, L. C. B. B., Nascimento, S. C., & Santos-Magalhães, N. S. (2004). Antitumor activity of *Cratylia mollis* lectin encapsulated into liposomes. *International Journal of Pharmaceutics*, 278(2), 435–445. <https://doi.org/10.1016/j.ijpharm.2004.01.043>
59. Priprem, A., Watanatorn, J., Sutthiparinyanont, S., Phachonpai, W., & Muchimapura, S. (2008). Anxiety and cognitive effects of quercetin liposomes in rats. *Nanomedicine*, 4(1), 70–78. <https://doi.org/10.1016/j.nano.2007.09.001>
60. Zhou, B. (2005). Evidence for  $\alpha$ -tocopherol regeneration reaction of green tea polyphenols in SDS micelles. *Free Radical Biology and Medicine*, 38(1), 78–84. <https://doi.org/10.1016/j.freeradbiomed.2004.09.014>
61. Ajazuddin, S. (2010). Applications of novel drug delivery systems for herbal formulations. *Fitoterapia*, 81(7), 680–689. <https://doi.org/10.1016/j.fitote.2010.04.012>
62. Ahmad, N. (2019). Preparation of a novel curcumin nanoemulsion by ultrasonication and its comparative effects in wound healing and the treatment of inflammation. *RSC Advances*, 9(35), 20192–20206. <https://doi.org/10.1039/C9RA02436A>
63. Uner, M. (2007). Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. *International Journal of Nanomedicine*, 2(3), 289–300. <https://doi.org/10.2147/IJN.S2070>
64. Li, H. (2009). Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. *Journal of Controlled Release*, 133(3), 238–244. <https://doi.org/10.1016/j.jconrel.2008.11.011>
65. Harshita, M. A. (2019). Paclitaxel-loaded nanolipidic carriers with improved oral bioavailability and anticancer activity against human liver carcinoma. *AAPS PharmSciTech*, 20(2), 87. <https://doi.org/10.1208/s12249-019-1387-0>
66. Choubey, A. (2011). Phytosome—a novel approach for herbal drug delivery. *International Journal of Pharmaceutical Sciences and Research*, 2(4), 807–812.
67. Mandle, . N. ., & Rathor, S. (2025). Transdermal Use of Curcumin Nanoemulsion: Preparation and Assessment. *Journal of Pharmaceutical Research and Integrated Medical Sciences*, 2(1), 59-71.
68. Hegmann, T. (2007). Nanoparticles in liquid crystals: Synthesis, self-assembly, defect formation, and potential applications. *Journal of Inorganic and Organometallic Polymers and Materials*, 17(3), 483–508. <https://doi.org/10.1007/s10904-007-9110-1>
69. Masson, D. S. (2005). Polyhydroxy alcohols and peach oil addition influence on liquid crystal formation and rheological behavior of O/W emulsions. *Journal of Dispersion Science and Technology*, 26(4), 463–468. <https://doi.org/10.1081/DIS-200056628>
70. Chanda, R. ., & Kumar, D. . (2025). Itraconazole Nanoemulsion Formulation and Assessment for Improved Oral Bioavailability. *Journal of Pharmaceutical Research and Integrated Medical Sciences*, 2(1), 17-29
71. Dos Santos, O. D. H., Miotto, J. V., de Moraes, J. M., da Rocha-Filho, P. A., & de Oliveira, W. P. (2005). Attainment of emulsions with liquid crystal from marigold oil

- using the required HLB method. *Journal of Dispersion Science and Technology*, 26(2), 243–249. <https://doi.org/10.1081/DIS-200049858>
72. Alam, M. S. (2017). Gum ghatti mediated, one-pot green synthesis of optimized gold nanoparticles: Investigation of process-variables impact using Box–Behnken based statistical design. *International Journal of Biological Macromolecules*, 104, 758–767. <https://doi.org/10.1016/j.ijbiomac.2017.06.046>
73. Barkat, M. A. (2019). Silver nanoparticles and their antimicrobial applications. *Current Nanomedicine*, 8(3), 215–224.
74. Verma VS, Sahu M. Synthesis And Characterization of Novel Organometallic Complexes for Catalytic Applications. *Journal of Pharmaceutical Research and Integrated Medical Sciences* [Internet]. 2025;2(4):60–70. Available from: <https://www.aktpublication.com/index.php/jprimis/article/view/61>.
75. Barkat, M. A. (2018). Current progress in synthesis, characterization, and applications of silver nanoparticles: Precepts and prospects. *Recent Patents on Anti-Infective Drug Discovery*, 13(1), 53–69. <https://doi.org/10.2174/1872213188666180124153444>
76. Tanwar DS, Kashyap G, Pandey A, Mahant H, Verma VS. Structure-Based Drug Design of Kinase Inhibitors for Targeted Cancer Therapy. *Indian Journal of Pharmaceutical Chemistry and Analytical Techniques* [Internet]. 2025;136–48. Available from: [https://www.researchgate.net/publication/394387152\\_Structure-](https://www.researchgate.net/publication/394387152_Structure-)
77. Hasnain, M. S. (2019). Purple heart plant leaves extract-mediated silver nanoparticles synthesis: Optimization by Box–Behnken design. *Materials Science and Engineering C*, 99, 1105–1114. <https://doi.org/10.1016/j.msec.2019.02.049>
78. Barkat, M. A. (2019). Nanopaclitaxel therapy: An evidence-based review on the battle for next-generation formulation challenges. *Nanomedicine*, 14(10), 1323–1341. <https://doi.org/10.2217/nnm-2019-0145>
79. Anselmo, A. C., & Mitragotri, S. (2016). Nanoparticles in the clinic. *Bioengineering & Translational Medicine*, 1(1), 10–29. <https://doi.org/10.1002/btm2.10003>
80. Ventola, C. L. (2017). Progress in nanomedicine: Approved and investigational nanodrugs. *Pharmacy and Therapeutics*, 42(12), 742–755.